Kazumi Nishino - Concepedia

Author

Kazumi Nishino

Osaka International Cancer Institute ORCID

Also Known As

K Nishino, K. Nishino, KAZUMI NISHINO, Kazumi Nishino, Nishino K., Nishino, K., Nishino, Kazumi, Rachel Sanborn

328

Publications

Citations

H-Index

Concepts

All Affiliations

Osaka International Cancer Institute National Cancer Center Hospital East Kindai University Sendai Kousei Hospital The University of Osaka

About

Kazumi Nishino is an author at Osaka International Cancer Institute specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	29	987
2	Health Sciences	3	3	131
3	Public Health	1	1	64
4	Allergy	1	1	24
5	Biostatistics	1	1	64

Kazumi Nishino

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Quantitative Detection of <i>EGFR</i> Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas Kazuya Taniguchi, Junji Uchida, Kazumi Nishino, Clinical Cancer Research	2011	314
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, JAMA Oncology	2021	178
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori, Journal of Thoracic Oncology	2022	150
Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo Toru Arai, Kinya Abe, Hiroto Matsuoka, American Journal of Physiology-Lung Cellular and Molecular Physiology	2000	129
Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA Junji Uchida, Kikuya Kato, Yoji Kukita, Clinical Chemistry	2015	112
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial Motohiro Tamiya, Akihiro Tamiya, Takako Inoue, PLoS ONE	2018	105
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Journal of Clinical Oncology	2024	99
Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor Koji Takano, Manabu Kinoshita, Masatoshi Takagaki, Neuro-Oncology	2015	98
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, Journal of Clinical Oncology	2024	91
Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer Toshiki Funakoshi, Isao Tachibana, Yoshihiko Hoshida, Oncogene Oncogenic AgentMedicineImmunologyTumor SuppressorCancer Biology	2003	87

Page 1